Generic Plavix Will Slow U.S. Pharmaceutical Sales Growth In 2006 – IMS
Executive Summary
The launch of generic Plavix (clopidogrel) could reduce overall pharmaceutical sales growth for 2006 by nearly one percent, IMS Health VP-Industry Relations Doug Long suggested
You may also be interested in...
Teva Touts CNS-Focused Branded Pipeline, Expects 15 Filings By 2015
Teva's expansion of its branded drug business will focus on central nervous system therapies, with one of its first regulatory submissions, an NDA for a 40 mg/day dose of multiple sclerosis treatment Copaxone,slated for 2009
Teva Touts CNS-Focused Branded Pipeline, Expects 15 Filings By 2015
Teva's expansion of its branded drug business will focus on central nervous system therapies, with one of its first regulatory submissions, an NDA for a 40 mg/day dose of multiple sclerosis treatment Copaxone,slated for 2009
Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi
The impact of the launch of a generic version of Plavix - the second best selling drug in the world - will continue to weigh on Sanofi-Aventis and Bristol-Myers Squibb at least through the remainder of the year and possibly beyond despite a ruling in their favor barring Apotex' sale of generic clopidogrel